PROPANC BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
PROPANC BIOPHARMA, INC. (PPCB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -2.48% for the 12-month period ending 2018-06-30, per its 10-K filed 2018-09-17.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2018-09-17
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was -2.48%.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was -3.74%.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2016 was -3.74%, a 268.47% decline from fiscal 2015.
- PROPANC BIOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2015 was 2.22%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2018-06-30 | -2.48% 10-K · filed 2018-09-17 | |
| 2017-06-30 | -3.74% 10-K · filed 2018-09-17 | |
| 2016-06-30 | -3.74% 10-K · filed 2017-09-28 | 0.76% 10-K · filed 2016-09-28 |
| 2015-06-30 | 2.22% 10-K · filed 2016-09-28 | -2.22% 10-K · filed 2015-09-30 |
| 2014-06-30 | -5.50% 10-K · filed 2015-09-30 | |
| 2013-06-30 | -4.02% 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |